Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have earned an average rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $45.10.

AVTX has been the subject of a number of recent analyst reports. Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Guggenheim set a $48.00 price target on Avalo Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 7th. Citizens Jmp dropped their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Avalo Therapeutics in a research note on Friday, July 24th.

Insider Activity at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the sale, the insider owned 51,776 shares of the company’s stock, valued at approximately $931,968. This represents a 2.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System acquired a new position in Avalo Therapeutics during the second quarter valued at approximately $196,000. Dimensional Fund Advisors LP acquired a new stake in shares of Avalo Therapeutics in the 3rd quarter valued at $143,000. Boothbay Fund Management LLC acquired a new stake in shares of Avalo Therapeutics in the 2nd quarter valued at $56,000. AlphaCentric Advisors LLC bought a new position in shares of Avalo Therapeutics in the 1st quarter valued at $174,000. Finally, Jump Financial LLC bought a new position in shares of Avalo Therapeutics in the 4th quarter valued at $238,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Trading Down 1.3%

Shares of AVTX stock opened at $19.34 on Tuesday. The stock has a market cap of $1.04 billion, a P/E ratio of -4.43 and a beta of 0.80. Avalo Therapeutics has a 1 year low of $8.65 and a 1 year high of $24.27. The stock has a 50 day simple moving average of $19.03 and a 200 day simple moving average of $16.82.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). Analysts forecast that Avalo Therapeutics will post -2.59 EPS for the current year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.